AI
Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
01/11/21, 1:24 PM
Location
boston
Money raised
$30 million
Sensei Biotherapeutics, Inc., a clinical-stage cancer immunotherapy company, today announced the successful closing of a $30 million Series B financing. The financing was co-led by existing investor Apeiron Investment Group and new investor Catalio Capital Management. Additional investments included new investors Pura Vida Investments and several international family offices, as well as existing investors Cambrian Biopharma, Moore Strategic Ventures, Steve Jurvetson’s Future Ventures, and Presight Capital.
Company Info
Location
boston, massachusetts, united states
Additional Info
Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary phage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating agents that fully engage the immune system. Using its proprietary ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage called Phortress™ targeting multiple tumor associated antigens to treat patients using a personalized yet off the shelf cocktail approach. The platform enables efficient, scalable and cost-effective manufacturing to support all clinical programs. Its most advanced program, SNS-301, a first-in-class ImmunoPhage™ targeting Aspartyl beta Hydroxylase (ASPH) in advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN), is currently enrolling patients in a Phase 1/2 clinical trial. Its earlier stage programs include SNS-401, a ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma and SNS-VISTA, antibody-based therapeutic targeting V-domain Ig suppressor of T cell activation (VISTA). The company brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. For more information, please visit www.senseibio.com.
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.
Related people
AH